Amphastar Pharma (AMPH) Tops Q2 EPS by 22c
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2016
August 8, 2016 4:06 PM EDTRANCHO CUCAMONGA, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended June 30, 2016.
Second Quarter Highlights
Net revenues of $68.0 million for the second quarterGAAP net income of $6.9 million, or $0.15 per diluted share for the second quarterAdjusted non-GAAP net income of $10.3 million, or $0.23 per diluted share for the second quarterDr. Jack Zhang, Amphastars CEO, commented:Â Resubmitting... More